Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (Nasdaq: CSTL) will present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m. Eastern time, with a live audio webcast and replay available on its investor relations website. The company will also participate in one-on-one investor meetings at the 10th annual Lake Street Best Ideas Growth (BIG10) Conference on Thursday, Sept. 10, 2026, with meetings requested exclusively through Lake Street Capital Markets.
Castle Biosciences (Nasdaq: CSTL) has been approved for a dual listing of its common stock on Nasdaq Texas, a new Dallas-based exchange. The company will retain its primary listing on The Nasdaq Global Market, and trading on Nasdaq Texas is expected to begin today under the existing ticker CSTL.
According to Castle Biosciences, the dual listing aims to deepen its ties to Texas, enhance investor engagement and visibility, and support Texas’ development as a life sciences hub. The company stated that the move will not affect investors’ ability to trade its shares, nor its operations, reporting obligations, or capital structure.
Castle Biosciences (Nasdaq: CSTL) reported Q2 2026 revenue of $103.5 million, up from $86.2 million in Q2 2025. Core test volumes (DecisionDx-Melanoma and TissueCypher) grew 32%. Q2 gross margin was 75% (Adjusted 76%). Net loss was $2.1 million, or $0.07 per share, versus net income of $4.5 million in the prior-year quarter, while Adjusted EBITDA increased to $12.4 million.
For the first half of 2026, revenue reached $187.2 million and net loss was $16.6 million. Cash, cash equivalents and marketable securities totaled $266.8 million at June 30, 2026. Castle raised its 2026 total revenue guidance to $365–375 million and now expects positive Adjusted EBITDA in Q3, Q4 and full-year 2026. Recent highlights include New York State assay approval and award recognition for the AdvanceAD-Tx test and publication of additional clinical evidence supporting DecisionDx-Melanoma.
Castle Biosciences (Nasdaq: CSTL) announced that its executive management will present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time. A live audio webcast and subsequent replay will be accessible via the company’s investor relations events webpage.
Castle Biosciences (Nasdaq: CSTL) received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx™ gene expression profile test, a non-invasive assay designed to guide systemic therapy selection in patients aged 12 and older with moderate-to-severe atopic dermatitis (AD).
According to Castle Biosciences, AdvanceAD-Tx classifies patients into either a JAK Inhibitor Responder Profile or a Th2 Molecular Profile using a simple skin sample, providing molecular insight to support treatment choice. With this decision, Castle now has NYSDOH approval for all tests in its dermatology and ophthalmology portfolios, its TissueCypher test in gastroenterology, and its clinical laboratories in Phoenix and Pittsburgh.
Castle Biosciences (Nasdaq:CSTL) will release its second quarter 2026 financial results after the market close on Thursday, July 30, 2026. Company management will host a webcast at 4:30 p.m. Eastern time to discuss the results, followed by a Q&A session.
Castle Biosciences (Nasdaq:CSTL) reported prospective, multicenter DECIDE study results showing its DecisionDx-Melanoma i31-SLNB risk prediction outperformed the MIA nomogram for sentinel lymph node (SLN) positivity in cutaneous melanoma.
In 912 patients, i31-SLNB low-risk cases had 2.6% observed SLN positivity vs 5.8% for MIA; overall AUC was 0.74 vs 0.61 (p=0.001).
Castle Biosciences (Nasdaq:CSTL) announced that chief financial officer Frank Stokes was named a 2026 CFO Awards honoree by the Houston Business Journal. He is one of 22 CFOs recognized in Greater Houston for financial leadership and organizational impact.
Stokes has served as CFO since December 2017, helping guide Castle Biosciences’ 2019 Nasdaq IPO and supporting growth through multiple strategic acquisitions. Honorees will be celebrated July 30 and featured in the July 31 print and digital issues.
Castle Biosciences (Nasdaq:CSTL) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4). On June 15, 2026, its Compensation Committee granted RSUs covering 204,925 shares of common stock to 172 new employees under the 2022 Inducement Plan, vesting over four years.
Castle Biosciences (Nasdaq:CSTL) announced that its AI-derived TissueCypher Barrett's Esophagus Test has exceeded 100,000 clinical orders as of June 16, 2026. The test is designed to predict a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, helping clinicians tailor management decisions.